Author

A. Talas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:deep learning· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

E. Welker· 2 shared P. I. Kulcsar· 2 shared A. Cremonesi· 1 shared B. Thoeny· 1 shared C. Schwerdel· 1 shared D. A. Simon· 1 shared D. Boeck· 1 shared E. A. Villiger· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

E. Welker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Treatment of a genetic liver disease in mice through transient prime editor expression

T. Rothgangl, E. I. Ioannidi, Y. Weber, A. Talas, D. Boeck, M. Matsushita, E. A. Villiger, L. Schmidheini, J. Moon, P. J. C. Lin, S. H. Y. Fan, K. F. Marquart, C. Schwerdel, N. Rimann, E. Faccin, , G. Schwank

This paper demonstrates transient prime editor expression in mice to correct a genetic liver disease, reducing blood phenylalanine levels below the therapeutic threshold.

bioRxiv · Jan 22, 2024 · PreprintBioengineering

PEAR: a flexible fluorescent reporter for the identification and enrichment of successfully prime edited cells

D. A. Simon, A. Talas, P. I. Kulcsar, E. Welker

PEAR is a fluorescent reporter that identifies and enriches prime-edited cells, increasing the edited population by up to 70%.

bioRxiv · Apr 26, 2021Bioengineering

Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage

P. I. Kulcsar, A. Talas, K. Huszar, Z. Ligeti, E. Toth, N. Weinhardt, E. Fodor, E. Welker

The paper develops HeFSpCas9 variants by combining mutations from eSpCas9 and SpCas9-HF1 to improve specificity and cleavage, showing that no single variant is universally optimal.

bioRxiv · Sep 12, 2017Bioengineering